Measuring social functioning with the personal and social performance scale in patients with acute symptoms of schizophrenia: interpretation of results of a pooled analysis of three Phase III trials of paliperidone extended-release tablets.

Journal article

BACKGROUND: The safety and efficacy of paliperidone extended-release tablets (paliperidone ER) in patients with acute symptoms of schizophrenia have been described in 3 randomized, double-blind, 6-week, placebo-controlled, fixed-dose, Phase III clinical trials. The validity and reliability of the Personal and Social Performance (PSP) scale, both in patients with acute symptoms of schizophrenia and those with stabilized symptoms, have also been reported. OBJECTIVE: The aim of this work was to...

Expand abstract

Authors: Patrick, D; Burns, T; Morosini, P; Gagnon, D; Rothman, M

• Publication status: Published
• Journal: Clinical therapeutics
• Volume: 32
• Issue: 2
• Pages: 275-292
• Publication date: 2010-02-01
• DOI: 10.1016/j.clinthera.2010.02.003
• EISSN: 1879-114X
• ISSN: 0149-2918
• Language: English
• Keywords: Placebo Effect; Male; Dose-Response Relationship, Drug; Antipsychotic Agents; Psychiatric Status Rating Scales; Schizophrenic Psychology; Multicenter Studies as Topic; Social Behavior; Time Factors; Pyrimidines; Randomized Controlled Trials as Topic; Tablets; Isoxazoles; Clinical Trials, Phase III as Topic; Treatment Outcome; Administration, Oral; Delayed-Action Preparations; Double-Blind Method; Female; Humans; Schizophrenia; Adult